We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

6,600 Open access books available
178,000 International authors and editors
195M Downloads

154 Countries delivered to
TOP 1% Our authors are among the most cited scientists
12.2% Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
1. Introduction

Acute coronary syndrome is a clinical condition of partial or total obstruction of blood flow in the coronary artery due to acute thrombus formation. Culprit vessel, coronary artery segment within which the site of origin of thrombus formation lies, is occupied by eroded or ruptured atherosclerotic plaque. Direct contact between circulating blood constituent and atherosclerotic plaque content owing to loss of endothelial cell barrier orchestrates the haemostasis events, i.e. thrombus formation and coagulation activation. Evolved within years of human life span, atherosclerotic undergoes three main steps: initiation, progression and finally complication (Libby, 2002).

Atherosclerotic plaque development involves cellular and molecular interactions as well as blood flow dynamic alterations in the affected area. Although these steps affect all individual, some gather the risk factors to develop progression and complication of coronary atherosclerotic lesion faster and more prominent than others. Given the dynamic nature of these steps, understanding several mechanisms engage in every step will provide insight into therapeutic approach. Here, we review the last two steps of coronary atherosclerotic plaque development, with the focus in the role of platelets, anucleated cells being the target for therapeutic advancement in atherosclerosis and acute coronary syndrome.

2. Formation of atherosclerotic plaque

The earliest event of atherosclerosis formation is the retention of apolipoprotein B–containing lipoproteins from circulation into subendothelial of the arterial wall (Tabas et al., 2007). This particular lipoprotein interacts with subendothelial proteoglycan through ionic affinity and hence instigates lipoprotein retention in the intimal layer, the innermost part of the arterial wall (Borén et al., 1998; Skalen et al., 2002). During this stage, the tendency of
retention of lipoprotein depends greatly on sustained plasma level of apolipoprotein B-containing lipoproteins and, in the lesser degree, lipoprotein size, charge, and composition as well as endothelial permeability (Tabas et al., 2007). Three classes of lipoproteins have apolipoprotein B as integral constituent: very low density lipoproteins (VLDL), intermediate density lipoproteins (IDL), and low density lipoproteins (LDL) (Sniderman et al., 1991). Among them, LDL has the biggest apolipoprotein B proportion and is the most likely to interact with subendothelial proteoglycan (Sniderman et al., 1991).

Modification of LDL apolipoprotein B entrapped in intimal layer by oxidative mechanism results in oxidative LDL (oxLDL) (Stocker & Keaney, 2004). Smooth muscle cells, endothelial cells and macrophages are capable to modify LDL via oxidative modification (Diaz et al., 1997). OxLDL is susceptible to scavenging macrophages and gives rise to the generation of cholesterol-laden foam cells (Stocker & Keaney, 2004). OxLDL continuously activates adjacent endothelial cells. Activated endothelial cells express adhesion molecules on their luminal surfaces which attract inflammatory cells from circulation, mainly monocytes and lymphocytes which transmigrate to intimal layer. The blend of inflammatory and resident vascular cells promotes the formation of atherosclerotic plaque. Arterial smooth muscle cells proliferate and migrate to the intimal layer in response to several growth factors releasing from chronic inflammation microenvironment in the intimal layer (Libby, 2002). Smooth muscle cells form a layer which envelopes the core of “inflammatory nidus” at the endothelial site, produce and release collagen and thus shape the so called fibrous cap. Below the cap, “inflammatory nidus” continuously attracts circulating LDL, modifies it and recognizes it as antigen which attracts more inflammatory cells.

Atherosclerotic plaque mainly composes of two constructions which undergo dynamic changes: fibrous cap and lipid-rich core. The theories of how plaque originated have been proposed. Response-to-injury theory proposes the initial step in atherogenesis is endothelial denudation due to injurious substance or forces leading to alteration of normal vascular homeostatic properties (Ross, 1993). Injury to endothelial cells enhances endothelial permeability and adhesiveness for leukocytes to attach and migrate into subendothelial. Here inflammation occurs and macrophage recruitment and platelet adhesion and aggregation take place, which promote procoagulant tendency of the plaque. Response-to-retention theory suggests LDL retention into subendothelial is the initial event and the prerequisite for plaque to form (Tabas et al., 2007). Endothelial injury does not play important role in this process, since plasma LDL is capable to cross normal endothelial cells through transcytosis mechanism and retains in subendothelial (Simionescu & Simionescu, 1993). Subsequent events are monocyte recruitment and lipid-laden macrophage formation which initiate subendothelial inflammation (Tabas et al., 2007). Oxidative modification theory indicates that to initiate plaque formation, subendothelial LDL should be modified chemically in order to attract macrophages’ scavenger receptor and be internalized to form foam cells (Stocker & Keaney, 2004). Native plasma LDL can enter subendothelial and is taken up by resident vascular cells via LDL receptor-mediated endocytosis. This native LDL does not initiate an inflammatory response and is not phagocytosed by monocytes, thus does not induce atherosclerosis (Torzewsky & Lackner, 2006).

As the plaque progress, fibrous cap is thinner and turn out to be fragile due to the imbalance of extracellular matrix metabolism, the infiltration of the fibrous cap by macrophages and foam cells, and the calcification process (Burnier et al., 2009). All of these contribute to fibrous cap weakening and lost its protective role. Once fibrous cap lose its integrity, it
exposes thrombogenic plaque to circulation. Platelets, around 150,000 until 450,000 per millilitre circulate in the blood without contacting endothelial cells, adhere to exposed site, are activated and initiate the event to seal the broken plaque surface. Unfortunately, this process gives rise to thrombus formation and acute coronary syndrome.

3. Activated platelet promotes progression of the plaque

Putative notion that platelets have role merely in the complicating stage of atherosclerosis has recently been challenged by several evidence indicating the wider involvement of platelets in both early and late atherosclerosis steps (Ruggeri, 2002; Gawaz et al., 2005). In histopathology study of human atherosclerosis, platelets were observed in the lesions, both in the free form and derivative form being phagocytozed by foam cells and macrophages (Sevitt, 1986). Platelet patrols the blood circulation ensuring the integrity of endothelial cells. Once this integrity disrupts, platelets expose to subendothelial component and rapidly undergo activation to form haemostasis thrombus; this is the case of plaque erosion or rupture in acute coronary syndrome. However, intact yet activated endothelial cells can also promote platelet activation, this is the case of progressed atherosclerosis plaque.

3.1 Role of platelet in progressed plaque dynamic

Advanced responses to modified apolipoprotein B-containing LDL through chronic and maladaptive inflammation, macrophage and foam cell apoptotic and plaque necrotic formation are representatives of progressed plaque (Tabas et al., 2007). Endothelial cells lining the plaque are continuously under activated state and express adhesion molecules and chemoattractant mediator in their surface. Monocytes and lymphocytes are attracted and adhere to these molecules and mediators, enter subendothelial and advance inflammatory state in the “inflammatory nidus” of the plaque (Lusis, 2000). The histomorphology of progressed plaque is characterized by the presence of large lipid-rich necrotic core, and a thin fibrous cap. Fibrous cap composes mainly of extracellular matrix produced by vascular smooth muscle cells (Lusis, 2000). Supportive function of fibrous cap relies on the integrity of this matrix which is maintained through fine balance between matrix production and degradation (Ross, 1993). In progressed plaque, the matrix degradation activity is increased in line with inflammatory activity in the “inflammatory nidus” of the plaque below the cap. Macrophage-derived proteases degrade extracellular matrix, thus weaken fibrous cap (Ross, 1993). Necrotic core of progressed plaque is derived from foam cells that endure apoptosis and necrotic. Initially, necrosis core is an acellular lipid-rich core, which predominantly consist of deposited lipids, such as cholesterol esters and free cholesterol derived mostly from retain LDL particles (Lusis, 2000). High toxicity of LDL oxidation and formation of reactive oxygen species damage the surroundings vascular cells, including foam cells (Madamanchi et al., 2005). The death of foam cells discharges extracellular lipids and cell debris into adjacent environments, thus promotes necrotic core formation (Lusis, 2000). Necrotic core enlarges and, in addition to free cholesterol, composes of cholesterol crystals, hyalinized hemorrhage and foam cell necrotic remnants (Virmani et al., 2000). Intimal calcifications, resulting from advance lipid oxidation and inflammatory cytokine reaction which modify osteogenic regulatory genes to promote osteogenesis, scatter in the base of necrotic core adjacent to the medial layer (Virmani et al., 2000; Abedin et al., 2004). Neovascularization in the intimal and
medial layer is another hallmark of progressed plaque (Fleiner et al., 2004). Hyperplastic network of vasa vasorum and ectopic neovascularization of the plaque are associated with intimal thickening, lipid contents and the degree of inflammation (Fleiner et al., 2004). The extent of these microvessels delivers a channel for entry of inflammatory cells into the plaque, boosting inflammation even more (Lusis, 2000). This blood vessel networks are fragile and prone to rupture and create an outward expansion of intraplaque hemorrhage that may overwhelm the integrity of the fibrous cap (Dickson & Gottlieb, 2003).

Thrombogenic property of lipid-rich necrotic core is determined by its collagen and tissue factor content. Two important direct platelet agonists dwell in the lipid-rich core, i.e lysophosphatidic acid which mediates platelet shape change during thrombus formation and collagen which induces platelet adhesion and aggregation (Lusis, 2000). Tissue factor, another major thrombogenic substrate in the lipid-rich core, is released by endothelial cells, smooth muscle cells, monocytes and macrophages or foam cells (Moons et al., 2002). The most abundant tissue factor site is in the necrotic core (Moons et al., 2002). Tissue factor activates coagulation cascade and promotes thrombus stability through fibrin network formation. Platelets are also capable in releasing tissue factor which give a hint of their role in supporting coagulation process (Zillmann et al., 2001).

3.2 Platelet-endothelial interaction promotes progressed plaque

Platelets have two storage granules, alpha and dense granules. Alpha granules contain adhesion molecules, chemokines, coagulation and fibrinolysis proteins, growth factors, and other proteins (Linden & Jackson, 2010). Dense granules contain molecules such as calcium, magnesium, phosphate and pyrophosphate, adenosine and guanosine triphosphate, adenosine and guanosine diphosphate and serotonin (Linden & Jackson, 2010). These granules develop in megakaryocytes, the progenitor cell of platelets. Platelet also contains lysosomes which have ubiquitous lysosomal membrane proteins: LAMP-1, LAMP-2, and CD63 (LAMP-3), acid hydrolases, cathepsins and other proteins (King & Reed, 2002).

In the alpha granules, platelet-specific proteins are synthesized only in megakaryocytes and deliver to platelets which undergo proteolytic upon platelet activation, which include platelet factor 4 (PF-4) and β-thromboglobulin (King & Reed, 2002). Platelet-selective proteins are synthesized principally by megakaryocytes but also in fewer number by few other cells and found in a larger concentration in platelets than plasma. These platelet-selective proteins include coagulation factor V, thrombospondin, P-selectin, and von Willebrand factor (King & Reed, 2002).

It is expected that platelets keep away from contact with vascular walls or other blood cellular components. Under steady laminar blood stream, platelets tend to flow away from endothelial cell surface area, avoiding connection with endothelial cells. Furthermore, intact and inactivated endothelial cell prevent platelet to adhere to its surface. Endothelial cells control platelet activity through inhibitory mechanisms involving cyclooxygenase 2 (Cox-2), prostacyclin or prostanoid synthetic systems (Gawaz, 2006). However, activated endothelial cells are capable to capture platelets and activated them, even without any endothelial damage (intact endothelial cells). Activated platelets will express several molecules, release their granule contents and stimulate surrounding cells, thus promoting plaque progression.
3.2.1 Rolling and adhering of platelet to endothelial cell surface

During inflammation, endothelial cells are activated and change their phenotype becoming prone to be adhesive for platelets (Gawaz, 2006). In vitro experiment showed that platelets adhere to activated human umbilical vein endothelial cells (HUVEC) which is mediated by fibrinogen, fibronectin and von Willebrand factor bound to platelets and endothelial cell receptors, ICAM-1, integrin αvβ3 and GPIb (Bombelli et al., 1998). In vivo experiment discloses that loose contact between platelets and activated endothelial cells precedes a tighter adhesion (Frenette et al., 1995). Rolling of platelets to activated endothelial cell is mediated by endothelial P-selectin and constitutively-expressed platelet P-selectin glycoprotein ligand 1 (PSGL-1) (Frenette et al., 1995; Frenette et al., 2002).

P-selectin is a type-1 membrane glycoprotein with a C-type lectin domain and is stored in the Weibel-Palade bodies of endothelial cells and alpha granules of platelets (Furie & Furie, 1995). It rapidly translocate to cell membrane upon endothelial cell or platelet activation (Frenette et al., 2002). PSGL-1 is an adhesion molecule primarily expressed in myeloid cells and T cells and functions as the main P-selectin ligand which mediates interactions between myeloid cells and endothelial cells as well as between myeloid cells and platelets (Vandendries et al., 2004). In the study of apoE-knock-out and the P-selectin gene deletion mice, atherosclerotic lesion development was significantly delayed, indicating the role of P-selectin as a key adhesion receptor in promoting advanced atherosclerosis (Dong et al., 2000). In early atherogenesis, it is likely that intact endothelial cells activate quiescent platelets through rolling mechanism via endothelial cell P-selectin and platelet PSGL-1 interaction. Endothelial cells coating atherosclerotic plaque are constantly under activated state, thus expressed P-selectin and attract platelets. P-selectin-expressed activated platelets bind to activated endothelial cells in a greater amount than non-activated platelets do.

In addition to platelet PSGL-1, platelet GPIbα is capable to interact with endothelial P-selectin and mediate platelet rolling (Gawaz et al., 2006). GPIbα is a component of GP Ib-IX-V complex which comprises four polypeptides: GP Ibα, GP Ibβ, GP IX, and GP V (Romo et al., 1999). GP Ib-IX-V complex bind to subendothelial von Willebrand factor, exposed when endothelial cell disrupted and initiate thrombosis. GPIbα contains von Willebrand factor-binding site and molecular structure nearly similar to PSGL-1 (Romo et al., 1999). Consequently, during endothelial cell activation, in addition to P-selectin, von Willebrand factor are also released from Weibel Palade body to the surface cell membrane. Both endothelial cell P-selectin and von Willebrand factor become the target for platelet GPIbα (Theilmeier et al., 2002). A study using mice deficient of von Willebrand factor showed some level of protection from atherosclerosis thus elucidated the role of von Willebrand factor on plaque formation and progression in intact endothelial cells (Methia et al., 2001).

3.2.2 Tight adhesion of platelet to endothelial cell surface

P-selectin-mediated loose contact is subsequently changed by tighter connection involving endothelial cell integrin, αvβ3 and platelet integrin, αIIbβ3 (Langer & Gawaz, 2008). Ligation of platelet GPIbα to endothelial cell von Willebrand factor during platelet rolling lead to activation of platelet integrin (Kasirer-Friede et al., 2002). Integrins are ubiquitous transmembrane α/β heterodimers that mediate cell-matrix and cell-cell interactions (Bennet, 2005). Platelets express 3 members of the β1 subfamily (αIIβ1, αβ1, and αvβ1) and 2 members of the β3 subfamily (αvβ3 and αIIbβ3) (Bennet, 2005). An αIIbβ3 is the most important integrin on platelets (Gawaz et al., 1991). In vitro and in vivo studies...
show that platelet αIIbβ3 and endothelial cell αvβ3 mediate firm contact between platelets and activated endothelial cells (Bombeli et al., 1998; Maasberg et al, 1999). By forming a bridge to fibrinogen, αIIbβ3 promotes arrest of platelets to adhesion molecules, intercellular adhesion molecule-1 (ICAM)-1, and to αvβ3 on activated endothelial cells (Bombeli et al., 1998; von Hundelshausen & Weber, 2007). Fibrinogen links platelet fibrinogen receptor on the surface of αIIbβ3 to the endothelial cell αvβ3 and forms the firm platelet adhesion to activated endothelial cells (Gawaz et al., 1991).

Fig. 1. Rolling of platelets to endothelial cells is mediated by platelet PSGL-1 and GP1bα bind to endothelial cell von Willebrand factor and P selectin.

It is worth mentioning that interaction between platelets and activated endothelial cells is not sufficient to promote thrombus formation. However, platelet adhesion to endothelial cells contributes to the progression of the plaque. Platelets mediate such effects through releasing products following adhesion and activation. The contents of storage granules are liberated upon platelet activation. It is estimated more than 300 proteins are secreted from activated platelets, which act in an autocrine or paracrine manner to modulate cell signaling and mediate the plaque progression (Coppinger et al., 2004). Endothelial cell chemotactic, adhesion, and proteolytic capacities are altered by paracrine modulation of substances released by adherent activated platelets. Here are the lists of platelet contents released upon adhesion and activation: (1) adhesion proteins (e.g., P-selectin, vitronectin, fibrinogen, fibronectin, von Willebrand factor, thrombospondin and αIIbβ3), (2) growth factors (e.g., PDGF, TGF-β, EGF and bFGF), (3) chemokines (e.g., RANTES, PF-4 and epithelial-neutrophil activating protein 78 (ENA-78)), (4) cytokine-like factors (e.g. IL-1β, CD40 ligand and β-thromboglobulin) and (5) coagulation factors (e.g. factor V, factor XI, PAI-1, plasminogen and protein S) (Gawaz et al., 2005).

In vitro study revealed that activated platelets coincubated with cultured endothelial cells gave rise to a secretion of MCP-1 and surface expression of ICAM-1 and αvβ3 on endothelial cells, which is mediated by an IL-1-dependent mechanism (Gawaz et al., 2000). MCP-1 is an effectual chemotactic factor for monocytes and ICAM-1 is an adhesion molecule which advocates monocyte and neutrophil recruitment to endothelial cells. This study emphasized
the important role of IL-1β on mediating endothelial cell activity upon platelet activation. IL-1 is the prototypic cytokine released by inflammatory cells and three members of the IL-1 gene family have been identified: IL-1, IL-1β, and IL-1 receptor antagonist (IL-1RA) (von Hundelshausen & Weber, 2007). Platelet activation induces rapid and persistent synthesis and release of IL1β and converts endothelial cell phenotype to become more adhesive to circulating neutrophils (Lindemann et al., 2001). Inhibition of β3 integrin attenuated the synthesis of platelet IL-1β, indicating firm adhesion of platelet to endothelial cells is prerequisite for IL-1β sustained secretion (Lindemann et al., 2001).

Fig. 2. Tight adhesion of platelets to endothelial cells is mediated by platelet αIIbβ3 bind to endothelial cell αvβ3, bridged by fibrinogen, and ICAM-1. This results in release of platelet contents (blue dots) which mediates endothelial activated molecules (green dots) expression.

Upon activation, platelet expresses CD40 ligand (CD40L) which ligates CD40 expressed by activated endothelial cells (Henn et al., 1998). Platelet CD40L and endothelial cell CD40 interaction amplifies the release of IL-8 and MCP-1 from endothelial cells and enhances the expression of endothelial cell adhesion receptors including E-selectin, VCAM-1, and ICAM-1 (Henn et al., 1998). In vivo study using mice deficient of platelet CD40L shows that platelet CD40L accelerate plaque formation and progression, mainly due to prevention of leukocyte recruitment (Lievens et al., 2010). This study implicates that platelet CD40L is important for recruitment of monocytes, neutrophils and lymphocytes during plaque intitiation and progression. Ligation of CD40L on endothelial cells promotes endothelial cell tissue factor expression, thus enhances a procoagulant phenotype on endothelial cells (Slupsky et al., 1998). Furthermore, it implicates in both the generation and secretion of matrix metalloproteinase-9 (MMP-9) and protease receptor urokinase-type plasminogen activator receptor (uPAR), thus promotes proteolytic activity on endothelial cells (May et al., 2002). Tight adhesion of platelet to endothelial cell via αIIbβ3 binding enhances platelet CD40L upregulation and matrix degradation (May et al., 2002). This endothelial-mediated matrix degradation is important in digestion of fibrous cap, thus promotes imbalance of matrix production and degradation and subsequently weakens the cap. This contributes to loss of cap protection and threatens plaque in rupture-prone condition.
PF-4, stored in platelet alpha granules, is the most abundant protein secreted by activated platelets. In histopathological study on human carotid atherosclerotic, PF-4 accumulates within macrophages of the plaque in the early lesion and continues to accumulate in foam cells and neovascular endothelial cells as lesion progressed (Pitsilos et al., 2003). PF-4 is deposited on the endothelial cell surface and retained by subendothelial proteoglycan (Aidoudi & Bikfalvi, 2010). PF-4 can activate endothelial cells by stimulating E-selectin expression (Yu et al., 2005). In vitro study indicates that PF-4 inhibits apolipoprotein B-containing LDL catabolism and facilitates retention of LDL on cell surface (Sachais et al., 2002). PF-4 blocks LDL uptake by LDL receptor expressed by vascular wall cells, thus increases its retention and prolongs its residence time in the vascular space which allows apolipoprotein-B to be modified and increases ox-LDL deposition (Nassar et al., 2002).

RANTES, secreted by activated platelets, triggers monocyte arrest and recruitment under flow conditions in vitro and in perfused carotid arteries (von Hundelshausen et al., 2001). Platelet P-selectin is important mediator of RANTES upregulation, indicates that RANTES is secreted during platelet rolling to endothelial cells (Schober et al., 2002). In atherosclerotic lesions and injury of apolipoprotein-E deficient mice, RANTES is expressed on endothelial cells (von Hundelshausen et al., 2001). Endothelial cells should have been modified by IL-1β, in order to receive the deposition of RANTES (Weyrich et al., 2002). Taken together, platelet-generated RANTES involves in atherosclerosis early in the beginning and more prominently in the plaque progression by modulating intimal hyperplasia and monocyte recruitment (Schober et al., 2002). Initial knowledge of ENA-78 activity is that this CXC chemokine superfamily member is synthesized and secreted by activated endothelial cells which give a proadhesive activity for neutrophils (Walz et al., 1997). Activated platelet expresses ENA-78 which attract leukocyte to adhere the endothelial cells (Schober et al., 2002). Furthermore, activated platelet-induced IL-1β action can stimulate endothelial cells to secret ENA-78 which encourage endothelial cell adhesiveness (Weyrich et al., 2002).

3.3 Platelet-leukocyte interaction enhances progressed plaque

Migration and recruitment of leukocytes into atherosclerotic plaque are essential steps of atherosclerosis progression. Leukocytes are captured and begin rolling on P-selectin expressing-endothelial cells. Leukocytes express PSGL-1 which engages in leukocyte rolling and attachment to P-selectin. Similar to that of platelet, P-selectin-mediated leukocyte binding to endothelial cells is a loose contact. This connection mediates rolling of leukocytes on the endothelial surface without firm attachment.

In addition to direct contact between leukocytes and endothelial cells, activated platelets interact with leukocyte as well. Among leukocytes, monocytes and lymphocytes are the first to be involved in atherogenesis and plaque progression.

3.3.1 Activated platelets bind and promote monocyte activation and transmigration

Monocytes are predominant leukocytes lodge in atherosclerotic plaque. Adherent platelets efficiently mediate monocyte rolling and arrest, even at high shear rate. Monocyte rolling is mediated by P-selectin on activated platelets and PSGL-1, constitutively expressed on monocytes (Kuijper et al., 1998). CD15, expressed by monocytes, has also been shown to bind platelet P-selectin (Larsen et al., 1990).

The initial connection between platelet P-selectin and monocyte PSGL-1 and CD15 is a loose attachment, and within rapid period it leads to elevated expression of the monocyte
integrin αMβ2 (membrane-activated complex 1 (Mac-1)) and makes tighter adhesion which support binding to platelet (Neumann et al., 1999). Monocyte Mac-1 has several counter-receptors expressed on activated platelet, such as GPIb, JAM-3 and ICAM-2 (Simon et al., 2000; Santos et al., 2002; Diacovo et al., 1994).

Platelet junctional adhesion molecule (JAM) supports platelet chemokine deposition and promotes monocyte recruitment (von Hundelshausen & Weber, 2007). JAM-3 is identified as a counter-receptor on platelets for the monocyte Mac-1 and mediates platelet-monocytes interactions (Santoso et al., 2002). Mac-1 is also able to bind indirectly to platelet αIIbβ3 linked by soluble fibrinogen bridge (Gawaz et al., 1991). Furthermore, several protein-receptor complexes mediate platelet-monocyte adhesion, such as thrombospondin which form a bridging of the CD36-CD36 interaction in both monocytes and platelets, CD40L on the platelet which attach to monocyte CD40 and monocyte triggering receptor expressed on myeloid cell 1 (TREM-1) to platelet-expressed TREM-1 ligand (Van Gils et al., 2009).

The attachment of activated adherent platelets to monocytes induces monocyte activation through shedding, expressing and releasing functional proteins. Interaction between platelets and monocytes increases the expression and activity of chemotaxis (MCP-1 and MIP-1α), proteolysis (uPAR and MMP), thrombosis (tissue factors), activation (TNF-α and IL-8) and adhesion (Mac-1 and VLA-4) factors on monocytes as well as potentiates monocyte to macrophage differentiation (Gawaz et al., 2005). In this respect, platelet-monocyte interaction provides an atherogenic environment at the vascular wall that supports plaque formation and regression (Gawaz et al., 2005). Similar to adherent platelets, activated platelets circulating in blood stream can affect endothelial cell and leukocyte phenotype (Huo et al., 2003). Circulating activated platelets are detected in the blood of patients with atherosclerotic conditions, such as acute coronary syndromes (Sarma et al., 2002), stable coronary disease (Furman et al., 1998), and diabetes mellitus (Broijersen et al., 1998).

In vitro study shows that platelet P-selectin increases monocyte adhesion to endothelial cells (Theilmeier et al., 1999). In vivo study using apoE-knock-out mice reveals that circulating activated platelets, through platelet P-selectin, promote monocyte recruitment to atherosclerotic plaque and accelerate the formation of atherosclerotic lesions (Huo et al., 2002). Platelet P-selectin-mediated interactions lead to deposition of platelet-derived proinflammatory factors, RANTES and PF-4, to the vessel wall and monocytes, resulting in activation of monocyte integrins, increased monocyte recruitment and accelerate atherosclerosis (Huo et al., 2002). Inversely, at low levels, activated endothelial cells express PSGL-1 and bind P-selectin on platelets and monocytes, thus mediating monocyte tethering and platelet recruitment to the endothelial cells (Da Costa Martins, 2007).

Not only do adherent platelets form tight binding to monocyte, but also circulating activated platelets attach to monocyte and form platelet monocyte complex (PMC). PMC reflected great capacity of platelet activation and in lesser extent, monocyte activation (Van Gils et al., 2009). Activated platelets bind via P-selectin to its receptor on monocytes, PSGL-1, and form complexes (Van Gils et al., 2009). PMCs mediate monocyte tethering and adhering to endothelial cell surface, making adherent monocyte-PMC cluster and promoting monocyte, and probably platelet, transmigration into subendothelial plaque lesion (Da Costa Martins et al., 2004). PMC high adhesive capability to activated endothelial cell is due to increasing integrin activation on monocyte and subsequently, increasing cell adhesion to fibronectin, VCAM-1 and ICAM-1 (Da Costa Martins, 2006). Monocytes transmigrate into
the atherosclerotic plaque, and change phenotype, becoming macrophages which express scavenger receptors and digest oxLDL to become foam cells (Libby & Aikawa, 2001).

Fig. 3. Activated platelets recruit monocytes via platelet P selectin binding to monocyte PSGL-1 and CD15, subsequently stabilized by monocyte Mac-1 bind to counter receptors in platelets thus promoting monocyte adhesion and transmigration into subendothelial.

Monocytes are the main source of tissue factor, an important determinant of thrombogenic plaque (Lindmark et al., 2000). Along with more monocyte recruitment, macrophage proliferation and tissue factor production intensify, filling the plaque with inflammatory and thrombogenic material which promote plaque progression.

3.3.2 Activated platelets bind and promote lymphocyte activation and transmigration

Lymphocyte transmigration from circulation to atherosclerotic plaque follows three steps: selectin-mediated rolling, integrin-modulated adhesion and transmigration. The transmigration of all lymphocyte populations, i.e. T cells, B cells, and natural killer cells, are enhanced by activated platelets (Li, 2008). Activated platelets interact with lymphocytes through binding between platelet P-selectin and lymphocyte PSGL-1 forming a loose contact, which subsequently induces clustering of αL integrin and enhances lymphocyte firm adhesion via ICAM-1 binding (Atarashi et al., 2005). Among lymphocytes, T cells have stronger adhesive capacity than B cells, indicates that T cells are selectively recruited in mediation of P-selectin expressing cells (Li, 2008) Enhancement of T cell adhesion on subendothelial matrix is mediated by activated platelets through formation of platelet-T cell conjugates and via ligations of P-selectin, CD40L and αIIbβ3 integrins (Li, 2008).

In progressed atherosclerotic plaque, T cells make up nearly 10% to 20% of the cell population and assemble at sites which are prone to rupture and cause fatal thrombosis (Hansson et al., 2002). Most of the T cells in atherosclerotic lesions is T helper (CD3+ and CD4+) and T-cell antigen receptor positive (TCRβ+), which indicate a function of recognition of antigens presented by macrophages or dendritic cells (Hansson et al., 2002). They modulate cell mediated immunity through secretion of interferon (IFN-γ), IL-2, and IL-22 (Hansson et al., 2002). IFN-γ inhibits smooth muscle cell new collagen synthesis, which is essential in supporting fibrous caps, thus weakens fibrous cap and promotes rupture-prone
Plaque, Platelets, and Plug – The Pathogenesis of Acute Coronary Syndrome

4. Activated platelet plays important role in coronary atherothrombosis

Arterial thrombosis is the acute complication that develops on the chronic atherosclerosis lesion, i.e. atherothrombosis, and in the coronary artery it causes acute coronary syndromes, during which blood flow through coronary segment is partially or totally obstructed. Platelets are prominent constituents of the thrombi that occlude the lumen of arteries. In this regard, atherothrombosis is a term that describes the combination of acute, a complication, and chronic, a progression, events of arterial disease (Ruggeri, 2002). Platelets are involved in both processes, through promoting plaque progression and participating in ruptured plaque-driven thrombus formation (Ruggeri, 2002).

Inducing event of acute coronary syndrome is plaque rupture or erosion. Rupture of fibrous cap lining the plaque is account for 60–65% of occlusive thrombi and erosion of endothelial cells lining the plaque is responsible for the rest 35–40% (Dickson & Gottlieb, 2003). In the rupture-prone atherosclerotic plaque, fibrous cap maintains protective role for the integrity of the plaque and provides a barrier between the thrombogenic material in the necrotic core and circulating blood components, mainly platelets and coagulation factors (Libby & Aikawa, 2001). As plaque progressed, leukocyte-driven inflammation is heightened in the intimal layer. Inflamed leukocytes can hinder biosynthesis of collagen from smooth muscle cells and can themselves overexpress collagen-degrading proteinases which in turn give the condition of the imbalance between collagen synthesis and degradation, thus weakening the fibrous caps and lead to plaque rupture (Libby & Aikawa, 2001). Furthermore, leukocytes participate in augmentation the production of the procoagulant factor, primarily tissue factor, in plaque lesion and give rise to the high thrombogenicity of the plaque’s lipid core (Libby et al., 2010). In addition to intrinsic factor within plaque, vessel lumen shear stress contribution for rupture of the plaque is considerate as well, since lumen restricted-area surrounding the plaque causes a local rising in blood flow velocity. Wall shear rate may exceed considerably at the edge of a severe occlusion in a coronary artery. High shear stress may specifically enhance platelet reactivity to matrix extra cellular of plaque (Ruggeri, 2002). The main trigger for the formation of a thrombus is the loss of the endothelial cell barrier and exposure of thrombogenic subendothelial extracellular matrix components with circulating blood. The response of platelets to this event can be divided into three successive but closely integrated phases: adhesion, activation and aggregation (Ruggeri, 2002). Several indices of activated platelets in the circulating blood are increased in patients with coronary artery disease and acute coronary syndromes, such as platelet surface molecule expression, platelet-monocyte aggregates, platelet-neutrophil aggregates and soluble proteins releasing upon platelet activation, mainly soluble CD40L (sCD40L) (Linden et al., 2007; Setianto et al., 2010).

4.1 Platelet tethering and adhesion initiate atherothrombosis

Erosion or rupture of the plaque poses circulating platelets, some of them have already activated, with highly thrombogenic extra cellular matrix components of the lipid core
which contains several adhesive molecules such as collagen, von Willebrand factor, laminin, fibronectin and thrombospondin (Andrews & Berndt, 2004). These molecules, once exposed, provide ligands for various activated platelet surface receptors. Under low shear rate condition, such as in vein and large artery flow, the molecules bind to platelet receptors are collagen, fibronectin and laminin, whereas under higher shear rates, such as in small arteries and atherosclerotic vessel, collagen and von Willebrand factor are principal molecules to mediate platelet slackening, tethering and adhesion (Andrews & Berndt, 2004). The early step of atherothrombosis is tethering of platelets to the surface of rupture plaque and is accomplished through the interaction between platelet GPIbα and collagen-bound von Willebrand factor (Ruggeri, 2002) and platelet GPVI and collagen (Andrews & Berndt, 2004). GPIbα is the major ligand-binding subunit of GPIb-IX-V or von Willebrand factor receptor and, in addition to binding site for von Willebrand factor, contains partially overlapping binding sites for the leukocyte integrin Mac-1, α-thrombin, and P-selectin expressed on activated platelets or activated endothelial cells (Andrews & Berndt, 2004). GPVI is a collagen receptor of the immunoglobulin superfamily that forms a complex with the FcR γ-chain at the cell surface in human and mouse platelets (Andrews & Berndt, 2004).

Von Willebrand factor, stored both by alpha granules of platelets or Weibel-Palade body of endothelial cells, is an adhesive glycoprotein found in circulating blood or subendothelial matrix (Andrews & Berndt, 2004). Circulating von Willebrand factor, which amount is much higher than that in subendothelial matrix, can be immobilized in exposed collagen via collagen binding site and become the substrate for platelet GPIbα (Massberg et al., 2003). In addition to collagen-bound, circulating von Willebrand factor can also be immobilized by forming the multimeric connection to matrix-bound, platelet-bound or subendothelial von Willebrand factor (Ulrichs et al., 2005). Immobilized von Willebrand factor is capable to catch circulating platelets via binding with platelet GPIbα (Andrews & Berndt, 2004). Ligation of non-activated platelet GPIbα with collagen-bound von Willebrand factor is not stable enough and is intended mainly to slow down platelets and maintain them in the rupture site, where subsequently platelets will be activated through various receptors, mainly integrin, and stable adhesion is formed.

![Diagram](fig4.jpg)

Fig. 4. Plaque rupture exposes platelets to thrombogenic collagen which attract them to adhere via platelet GPVI bind to collagen and GPIbα bind to collagen-bound von Willebrand factor, initiate thrombus formation.
In addition to collagen-bound von Willebrand factor, collagen itself can capture non-activated circulating platelets through platelet GPVI. However, GPVI has only a low affinity for collagen which makes GPVI, same as GPIbα, incapable to mediate stable platelet adhesion. Ligation of GPVI during the initial contact between platelets and subendothelial collagen provides an activation signal through platelet integrins, αIIbβ3 and α2β1, which is essential for subsequent stable platelet adhesion and aggregation (Gawaz, 2004). Although not tightly adherent, this early adhesion of platelets is of adequate affinity to facilitate arrest at high shear rate, leading ultimately to much more stable integrin-mediated adhesion (Andrews & Berndt, 2004).

4.2 Platelet activation and aggregation enhance atherothrombosis

Platelet activation and aggregation are the ensuing steps that occur within minutes, marked by the accumulation of platelets into the haemostatic thrombus (Ruggeri, 2002). Collagen-bound von Willebrand factor and platelet GPIbα interaction convey signal activation of platelet integrin αIIbβ3 to undergo conformational changes which are compulsory for firm, irreversible platelet resting on the subendothelial matrix surface (Gawaz, 2004). Conformational changes of αIIbβ3 enable an exposure of fibrinogen binding site which form cross linking with αIIbβ3 on different platelets by fibrinogen bridge (Andrews & Berndt, 2004). Similarly, ligation of GPVI shifts platelet αIIbβ3 and α2β1 from a low to a high affinity state and contributes to stable platelet adhesion (Gawaz, 2004). Until this step, stable adhesion of platelets is promoted by irreversible binding of platelet αIIbβ3 to collagen-bound von Willebrand factor and platelet α2β1 to uncoated collagen. The integrin-dependent stable adhesion of platelets consequently leads to activation of adherent platelets. Activated platelets are receptive to wide range of agonists or stimulants and adhesive proteins. They express surface receptors, which, upon activation by agonists and adhesive proteins, stimulate internal signaling pathways that lead to further platelet activation, degranulation, and capacity enhancement to bind with other adhesive proteins or platelets. Transmembrane receptors are the main agonist-stimulated receptor families and greatly activated during thrombus formation. The important platelet receptors in this class are thrombin receptors (protease activation receptor (PAR-1 and PAR-4), ADP receptors (P2Y1, and P2Y12) and integrins (mainly αIIbβ3) (Freedman, 2005). Activation of platelets by thrombin through PAR-1 and PAR-4 receptors results in calcium flux, platelet shape change, and stimulation of a variety of platelet-signaling pathways (Freedman, 2005). Importantly, thrombin-PAR receptor interaction leads to activation of integrin αIIbβ3 receptor complex through inside-out signalling (Freedman, 2005).

In non-activated platelets, αIIbβ3, the most abundant platelet integrins, has a very low affinity for its ligands (Cosemans et al., 2008). However, platelet activation remarkably increases the capacity of αIIbβ3 to attach to its ligands, particularly fibrinogen, fibrin, fibronectin and von Willebrand factor (Cosemans et al., 2008). These soluble adhesive proteins are immobilized and are attached to activated αIIbβ3 on the surface of activated adherent platelets and become the substrate for more non-activated circulating platelet recruitment and aggregation (Ruggeri, 2002). The interaction of circulating platelets with adherent platelets carries on through activated αIIbβ3 cross linking between platelets bridged by soluble fibrinogen, thus form the platelet aggregates (Gawaz, 2004). Platelet activation increases the surface density of αIIbβ3, thus more soluble fibrinogen attach and bridge other platelets, makes cross linking and allows continuing platelet aggregation and
thrombus growth. The inhibition of interaction of platelet αIIbβ3 - von Willebrand factor and αIIbβ3 - fibrinogen by αIIbβ3 antagonists, i.e. tirofiban, abciximab and eptifibatide, is of potentially benefit in acute settings of coronary atherothrombosis, due to inhibition of platelet aggregation, thrombus growth and stability.

Fig. 5. Adhesion and activation of platelets form stable plug via platelet αIIbβ3 bind to collagen-bound von Willebrand factor and platelet α2β1 bind to collagen, thus stimulate release of platelet surface receptors (blue dots) receptive to agonists and adhesive proteins.

In addition to integrin activation, several means of activation responses of platelets include: mobilization of cytosolic calcium, secretion of ADP, shedding and secretion of CD40L, released of tromboxane A2 (TXA2) and formation of pseudopods which support an effective sealing of the denuded plaque area (Cosemans et al., 2008; Gawaz, 2004). ADP, secreted by dense granules of activated platelets, stimulates platelets in autocrine loop through its receptors, P2Y1 and P2Y12. P2Y1 activation mediates platelet shape change and initiates platelet aggregation by mobilization of intracellular calcium (Andre et al., 2003). P2Y12 activation by ADP signal mediates inhibition of adenyl cyclase and stabilizes platelet aggregates as well as participates in the firm adhesion by activating αIIbβ3 (Andre et al., 2003). Persistent signal to keep P2Y12 in active state is of paramount important to prevent platelet disaggregation and to maintain αIIbβ3 in its active conformation (Cosemans et al., 2008). In addition to autocrine loop, ADP also works in paracrine mechanism by stimulating and recruiting non activated circulating platelets and inducing them to undergo aggregation with adherent platelets (Gawaz, 2004). Antagonist for P2Y12, i.e ticlopidine and clopidogrel, has already been widely used in acute coronary syndrome.

CD40L, expressed and released by activated platelets, binds to activated αIIBβ3 and contributes in supporting platelet aggregate stability (Andre et al., 2002). Upon platelet activation, the cytosolic CD40L protein is exocytosed to the platelet plasma membrane from where it is also shed and release into circulation in soluble form, sCD40L (Andre et al., 2002). These transmembran and soluble forms are detected to be elevated in patients with acute coronary syndrome (Aukrust et al., 1999; Garlichs et al., 2001; Setianto et al., 2010). Both transmembrane and soluble CD40L can form a cluster with platelet αIIbβ3 and lead to more platelet activation and enhance thrombus formation and stabilization (Andre et al., 2002).
TxA2 is made from arachidonic acid and is secreted by activated adherent platelets. It strengthens the activation process after the release into the extracellular space and create platelet feedback activation by acting as autocrine and paracrine manner on its thromboxane platelet receptor (Gawaz, 2004). TxA2 has a vasoconstricting activity and thus favors formation of the thrombus by slowing down the blood flow (Gawaz, 2004). Aspirin induces a complete and permanent inhibition of platelet TxA2 production through the inactivation of cyclooxygenase. In addition to αIIbβ3-mediated stability, several other adhesion and signaling receptors contribute to thrombus stability, such as PECAM-1, JAM-A, JAM-C, ESAM, CD226, and Epk kinases/ephrins, which is enable the tight contact of one platelet with receptors on adjacent platelets (Brass et al., 2005).

5. Conclusion

Platelet is a key maker for progression of atherosclerotic plaque. Its ability to interact with activated endothelial cells and leukocytes, provide the milieu of inflammation and thrombus-prone environment in atherosclerotic plaque. Platelet, with relatively similar pattern, captures monocyte and lymphocyte and grants them the path to transmigrate into atherosclerotic plaque. Platelet is a central player during coronary plaque rupture. It starts and nurtures coronary thrombus formation and stabilization. Platelet-based therapeutic modalities for atherosclerosis and acute coronary syndrome are still in progressed studies with some of them yield beneficial effect while others inconclusive.

6. References

Abedin, M.; Tintut, Y.; & Demer, L.L. 2004. Vascular Calcification: Mechanisms and Clinical Ramifications. Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.24, No.7, (May 2004), pp:1161-1170, ISSN: 1079-5642.

Aidoudi, S. & Bikfalvi, A. 2010. Interaction of PF4 (CXCL4) With The Vasculature: A Role in Atherosclerosis and Angiogenesis. Thrombosis and Haemostasis, Vol.104, No.5, (November 2010), pp.941-948, ISSN:0340-6245.

André, P.; Prasad, K.S.S.; Denis, C.V.; He, M.; Papalia, J.M.; Hynes, R.O.; Phillips, D.R. & Wagner, D.D. 2002. CD40L Stabilizes Arterial Thrombi by A 3 Integrin–Dependent Mechanism. Nature Medicine, Vol.8, No.3, (March 2002), pp.247-252, ISSN:1078-8956.

André, P.; Delaney, S.M.; LaRocca, T.; Vincent, D.; DeGuzman, F.; Jurek, M.; Koller, B.; Phillips, D.R. & Conley, P.B. 2003. P2Y12 Regulates Platelet Adhesion/Activation, Thrombus Growth, and Thrombus Stability in Injured Arteries. The Journal of Clinical Investigation, Vol.112, No.3, (August 2003), pp.398-406, ISSN:0021-9738.

Andrews, R.K. & Berndt, M.C. 2004. Platelet Physiology and Thrombosis. Thrombosis Research, Vol.114, No.5-6, (2004), pp. 447-453, ISSN:0049-3848.

Atarashi, K.; Hirata, T.; Matsumoto, M.; Kanemitsu, N. & Miyasaka, M. 2005. Rolling of Th1 Cells Via P-Selectin Glycoprotein Ligand-1 Stimulates LFA-1-Mediated Cell Binding To ICAM-1. The Journal of Immunology, vol.174, no.3, (February 2005), pp.1424-1432, ISSN:0022-1767.

Aukrust, P.; Müller, F.; Ueland, T.; Berget, T.; Aaser, E.; Brunsvig, A.; Solum, N.O.; Forfang, K.; Froland, S.S. & Gullesstad, L. 1999. Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina. Possible Reflection of T
Lymphocyte and Platelet Involvement in The Pathogenesis of Acute Coronary Syndromes. Circulation, Vol. 100, No.6, (August 1999), pp.614-20, ISSN:0009-7322.

Bennet, J.S. 2005. Structure and Function of The Platelet Integrin aIIbβ3. Journal of Clinical Investigation, Vol.115, No.12, (December 2005), pp.3363–3369, ISSN:0021-9738.

Bombeli, T.; Schwartz, B.R. & Harlan, J.M. 1998. Adhesion of Activated Platelets to Endothelial Cells: Evidence For a GPIIbIIIa-Dependent Bridging Mechanism and Novel Roles for Endothelial Intercellular Adhesion Molecule 1 (ICAM-1), Alphavbeta3 Integrin, and GPIbalpha. Journal of Experimental Medicine, Vol.187, No.3, (February 1998), pp.329-339, ISSN:0022-1007.

Borén, J.; Olin, K.; Lee, I.; Chait, A.; Wight, T.N. & Innerarity, T.L. 1998. Identification of The Principal Proteoglycan-Binding Site in LDL. A Single-Point Mutation in Apo-B100 Severely Affects Proteoglycan Interaction Without Affecting LDL Receptor Binding. Journal of Clinical Investigation, Vol.101, No.12, (June 1998), pp.2658–2664, ISSN:0021-9738.

Brass, L.F.; Zhu, L. & Stalker, T.J. 2005. Minding The Gaps to Promote Thrombus Growth and Stability. Journal of Clinical Investigation, Vol.115, No.12, (December 2005), pp.3385–3392, ISSN:0021-9738.

Broijersen, A.; Hamsten, A.; Eriksson, M.; Angelin, B. & Hjemdahl, P. 1998. Platelet Activity In Vivo in Hyperlipoproteinemia–Importance of Combined Hyperlipidemia. Thrombosis and Haemostasis, Vol.79, No.2, (February 1998), pp.268–275, ISSN:0340-6245.

Burnier, L.; Fontana, P.; Angelillo-Scherrer, A. & Kwak, B.R. 2009. Intercellular Communication in Atherosclerosis. Physiology, Vol.24, No.1 (February 2009), pp.36-44, ISSN:1548-9213.

Coppinger, J.A.; Cagney, G.; Toomey, S.; Kislinger, T.; Belton, O.; McRedmond, J.P.; Cahill, D.J.; Emili, A.; Fitzgerald, D.J. & Maguire, P.B. 2004. Characterization of The Proteins Released From Activated Platelets Leads to Localization of Novel Platelet Proteins in Human Atherosclerotic Lesions. Blood, Vol.103, No.6, (March 2004), pp.2096-2104, ISSN:0006-4971.

Cosemans, J.M.E.M.; Iserbyt, B.F.; Deckmyn, H. & Heemskerk, J.W.M. 2008. Multiple Ways to Switch Platelet Integrins On and Off. Journal of Thrombosis and Haemostasis, Vol.6, No.8, (August 2008), pp.1253–1261, ISSN:1538-7933.

Da Costa Martins, P.; van den Berk, N.; Ulfman, L.H.; Koenderman, L.; Hordijk, P.L. & Zwaginga, J.J. 2004. Platelet-Monocyte Complexes Support Monocyte Adhesion to Endothelium by Enhancing Secondary Tethering and Cluster Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.24, No.1, (January 2004), pp.193-199, ISSN:1079-5642.

Da Costa Martins, P.A.; van Gils, J.M.; Mol, A.; Hordijk, P.L. & Zwaginga, J.J. 2006. Platelet-Monocyte Binding to Monocytes Increases The Adhesive Properties of Monocytes by Up-Regulating The Expression and Functionality of β1 and β2 Integrins. Journal of Leukocyte Biology, Vol. 79, No.3, (March 2006), pp.499-507, ISSN:0741-5400.

Da Costa Martins, P.; Garcia-Vallejo, J.; van Thielen, J.V.; Fernandez-Borja, M.; van Gils, J.M.; Beckers, C.; Horrevoets. A.J.; Hordijk, P.L. & Zwaginga, J.J. 2007. P-Selectin Glycoprotein Ligand-1 Is Expressed on Endothelial Cells and Mediates Monocyte Adhesion to Activated Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, Vol.27, No.5, (May 2007), pp.1023-1029, ISSN:1079-5642.
Diaz, M.; Frei, B.; Vita, J.A. & Keaney, J.F.Jr 1997. Antioxidants and Atherosclerotic Heart Disease. 1997. *The New England Journal of Medicine*, Vol.337, No.6, (August 1997), pp.408–416, ISSN:0028-4793.

Diacovo, T.G.; deFougerolles, A.R.; Bainton, D.F. & Springer, T.A. 1994. A Functional Integrin Ligand on The Surface of Platelets: Intercellular Adhesion Molecule-2. *The Journal of Clinical Investigation*, Vol.94, No.3, (September 1994), pp:1243-51, ISSN:0021-9738.

Dickson, B.C. & Gotlieb, A.I. 2003. Towards Understanding Acute Destabilization of Vulnerable Atherosclerotic Plaques. *Cardiovascular Pathology*, Vol.12, No.5, (September 2003), pp.237-248, ISSN:1054-8807.

Dong, Z.M.; Brown, A.A. & Wagner, D.D. 2000. Prominent Role of P-Selectin in the Development of Advanced Atherosclerosis in ApoE-Deficient Mice. *Circulation*, Vol.101, No.19, (May 2000), pp.2290-2295, ISSN:0009-7322.

Fleiner, M.; Kummer, M.; Mirlacher, M.; Sauter, G; Cathomas, G.; Krapf, R. & Biedermann, B.C. 2004. Arterial Neovascularization and Inflammation in Vulnerable Patients Early and Late Signs of Symptomatic Atherosclerosis. *Circulation*, Vol.110, No.18, (November 2004), pp.2843-2850, ISSN:0009-7322.

Freedman, J.E. 2005. Molecular Regulation of Platelet-Dependent Thrombosis. *Circulation*, Vol.112, No.17, (October 2005), pp.2725-2734, ISSN:0009-7322.

Frenette, P.S.; Johnson, R.C.; Hynest, R.O. & Wagner, D.D. 1995. Platelets Roll on Stimulated Endothelium In Vivo: An Interaction Mediated by Endothelial P-Selectin. *Proceedings of the National Academy of Sciences of the United States of America.*, Vol.92, No.16, (August 1995), pp.7450-7454, ISSN:0027-8424.

Frenette, P.S.; Denis, C.V.; Weiss, L.; Jurk, K.; Subbarao, S.; Kehrel, B., Hartwig, J.H.; Vestweber, D. & Wagner, D.D. 2002. P-Selectin Glycoprotein Ligand 1 (PSGL-1) is Expressed on Platelets and Can Mediate Platelet–Endothelial Interactions In Vivo. *Journal of Experimental Medicine*, Vol.191, No.8, (April 2000), pp.1413–1422, ISSN:0022-1007.

Furie, B. & Furie, B.C. 1995. The Molecular Basis of Platelet and Endothelial Cell Interaction with Neutrophils and Monocytes: Role of P-Selectin and The P-Selectin Ligand, PSGL-1. *Thrombosis and Haemostasis*, Vol.74, No.1, (July 1995), pp:224-227, ISSN:0340-6245.

Furman, M.I.; Benoit, S.E.; Barnard, M.R.; Valeri C,R.; Borbone, M.L.; Becker, R.C.; Hechtman, H.B. & Michelson, A.D. 1998. Increased Platelet Reactivity and Circulating Monocyte-Platelet Aggregates in Patients With Stable Coronary Artery Disease. *Journal of American College of Cardiology*, Vol.31, No.2, (February 1998), pp.352–358, ISSN:0735-1097.

Garlisch, C.D.; Eskafi, S.; Raaz, D.; Schmidt, A.; Ludvig, J.; Herrmann, M.; Klinghammer, L.; Daniel, W.G. & Schmeisser, A. 2001. Patients with Acute Coronary Syndromes Express Enhanced CD40 Ligand/CD154 on Platelets. *Heart*, Vol.86, No.6, (December 2001), pp.649-655, ISSN:1355-6037.

Gawaz, M.P; Loftus, J.C.; Bajt, M.L.; Frojmovic, M.M., Plow, E.F. & Ginsberg, M.H. 1991. Ligand Bridging Mediates Integrin Alpha IIbbeta3 (Platelet GPIIB-IIIa) Dependent Homotypic and Heterotypic Cell-Cell Interactions. *The Journal of Clinical Investigation*, Vol.88, No.4, (October 1991), pp.1128-1134, ISSN:0021-9738.

Garlichs, C.D.; Eskafi, S.; Raaz, D.; Schmidt, A.; Ludwig, J.; Herrmann, M., Klinghammer, L.; Daniel, W.G. & Schmeisser, A. 2001. Patients with Acute Coronary Syndromes Express Enhanced CD40 Ligand/CD154 on Platelets. *Heart*, Vol.86, No.6, (December 2001), pp.649-655, ISSN:1355-6037.

Gawaz, M.P; Loftus, J.C.; Bajt, M.L.; Frojmovic, M.M., Plow, E.F. & Ginsberg, M.H. 1991. Ligand Bridging Mediates Integrin Alpha IIbbeta3 (Platelet GPIIB-IIIa) Dependent Homotypic and Heterotypic Cell-Cell Interactions. *The Journal of Clinical Investigation*, Vol.88, No.4, (October 1991), pp.1128-1134, ISSN:0021-9738.
Acute Coronary Syndromes

Gawaz, M.; Brand, K.; Dickfeld, T.; Pogatsa-Murray, G.; Page, S.; Bogner, C.; Koch, W.; Schömig, A. & Neumann, F. 2000. Platelets Induce Alterations of Chemotactic and Adhesive Properties of Endothelial Cells Mediated Through an Interleukin-1-Dependent Mechanism. Implications for Atherogenesis. *Atherosclerosis*, Vol.148, No.1, (January 2000), pp.75-85, ISSN:0021-9150.

Gawaz, M. 2004. Role of Platelets in Coronary Thrombosis and Reperfusion of Ischemic Myocardium. *Cardiovascular Research*, Vol.61, No.3 (February 2004), pp.498–511, ISSN:0008-6363.

Gawaz, M.; Langer, H. & May, A.E. 2005. Platelets in Inflammation and Atherogenesis. *The Journal of Clinical Investigation*, Vol.115, No.12, (December 2005), pp.3378-3383, ISSN:0021-9738.

Gawaz, M. 2006. Platelets in The Onset of Atherosclerosis. *Blood Cells, Molecules, and Diseases*, Vol.36, No.2, (April 2006), pp.206–210, ISSN: 1079-9796.

Hansson, G.K.; Libby, P.; Schönbeck, U. & Yan, Z. 2002. Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. *Circulation Research*, Vol.91, No.4, (August 2002), pp.281-291, ISSN:0009-7330.

Henn, V.; Slupsky, J.R.; Gräfe, M.; Anagnostopoulos, I.; Förster, R.; Müller-Berghaus, G.; & Kroczyk, R.A. 1998. CD40 Ligand on Activated Platelets Triggers an Inflammatory Reaction of Endothelial Cells. *Nature*, Vol.391, No.6667, (February 1998), pp.517-615, ISSN:0028-0836.

Huo, Y.; Schober, A.; Forlow, S.B.; Smith, D.F.; Hyman, M.C.; Jung, S.; Littman, D.R.; Weber, C. & Ley, K. 2003. Circulating Activated Platelets Exacerbate Atherosclerosis in Mice Deficient in Apolipoprotein E. *Nature Medicine*, Vol.9, No.1 (January 2003), pp.61 – 67, ISSN:1078-8956.

Kasirer-Friede, A.; Ware, J.; Leng, L.; Marchese, P.; Ruggeri, Z.M. & Shattil, S.J. 2002. Lateral Clustering of Platelet GP Ib-IX Complexes Leads to Up-regulation of the Adhesive Function of Integrin αMβ3. *The Journal of Biological Chemistry*, Vol.277, No.14, (April 2002), pp:11949-11956, ISSN:0021-9258.

King, S.M. & Reed, G.L. 2002. Development of Platelet Secretory Granules. *Seminars in Cell & Developmental Biology*, Vol.13, No.4 (August 2002), pp.293–302, ISSN:1084-9521.

Kuijper, P.H.; Gallardo Torres, H.I.; Houben, L.A.; Lammers, J.W.; Zwaginga, J.I. & Kenderman, L. 1998. P-selectin and MAC-1 Mediate Monocyte Rolling and Adhesion to ECM-Bound Platelets Under Flow Conditions. *Journal of Leukocyte Biology*, Vol.64, No.4, (October 1998), pp.467–473, ISSN:0741-5400.

Langer, H.F. & Gawaz, M. 2008. Platelet-vessel Wall Interactions in Atherosclerotic Disease. *Thrombosis and Haemostasis*, Vol.99, No.5, (May 2008), pp.480-486, ISSN:0340-6245.

Larsen, E.; Palabrina, T.; Sajer, S.; Gilbert, G.E.; Wagner, D.D.; Furie, B.C. & Furie, B. 1990. PADGEM-Dependent Adhesion of Platelets to Monocytes and Neutrophils Is Mediated By A Lineage-Specific Carbohydrate, LNF III (CD15). *Cell*, Vol.63, No.3, (November 1990), pp.467-474, ISSN:0092-8674.

Li, N. 2008. Platelet-lymphocyte Cross-talk. *Journal of Leukocyte Biology*, Vol.83, No.5, (May 2008), pp.1069–1078, ISSN:0741-5400.

Libby, P. 2002. Inflammation in Atherosclerosis. *Nature*, Vol.420, No.19/26, (December 2002), pp.868-874, ISSN:0028-0836.

www.intechopen.com
Libby, P. & Aikawa, M. 2001. Evolution and Stabilization of Vulnerable Atherosclerotic Plaques. *Japanese Circulation Journal*, Vol.65, No.6, (June 2001), pp.473–479, ISSN:0047-1828.

Libby, P.; Okamoto, Y.; Rocha, V.Z. & Folco, E. 2010. Inflammation in Atherosclerosis: Transition from Theory to Practice. *Circulation Journal*, Vol.74, No.2, (February 2010), pp.213-220, ISSN:1346-9843.

Lievens, D.; Zernecke, A.; Seijkens, T.; Soehnlein, O.; Beckers, L.; Munnix, I.C.A.; Wijands, E.; Goossens, P.; van Kruchten, R.; Thevissen, L.; Boon, L.; Flavell, R.A.; Noelle, R.J.; Gerdes, N.; Biessen, E.A.; Daemen, M.J.A.P.; Heemskerk, J.W.M.; Weber, C. & Lutgens, E. 2010. Platelet CD40L Mediates Thrombotic and Inflammatory Processes in Atherosclerosis. *Blood*, Vol.116, No.20, (November 2010), pp.4317-4327, ISSN:0006-4971.

Lindemann, S.; Tolley, N.D.; Dixon, D.A.; McIntyre, T.M.; Prescott, S.M.; Zimmerman, G.A. & Weyrich, A.S. 2001. Activated Platelets Mediate Inflammatory Signaling by Regulated Interleukin 1β Synthesis. *The Journal of Cell Biology*, Vol.154, No.3, (August 2001), pp.485-490, ISSN:0021-9525.

Linden, M.D.; Furman, M.I.; Frelinger III, A.L.; Fox, M.L.; Barnard, M.R.; Li, Y.; Przyklenk, S.K. & Michelson, A.D. 2007. Indices of Platelet Activation and The Stability of Coronary Artery Disease. *Journal of Thrombosis and Haemostasis*, Vol.4, No.5, (April 2007), pp.761–765, ISSN:1538-7933.

Linden, M.D. & Jackson, D.E. 2010. Platelets: Pleiotropic Roles in Atherogenesis and Atherothrombosis. *The International Journal of Biochemistry & Cell Biology*, Vol.42, No.11, (November 2010), pp.1762-1766, ISSN:1357-2725.

Lindmark, E.; Tenno, T. & Siegbahn, A. 2000. Role of Platelet P-Selectin and CD40 Ligand in The Induction of Monocytic Tissue Factor Expression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol. 20, No.10, (October 2000), pp.2322-2328, ISSN:1079-5642.

Lusis, J.A. 2000. Atherosclerosis. *Nature*, Vol.407, No.6801, (September 2000), pp.233-240, ISSN:0028-0836.

Madamanchi, N.R.; Vendrov, A. & Runge, M.S. 2005. Oxidative Stress and Vascular Disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol.25, No.1, (January 2005), pp.29–38, ISSN:1079-5642.

Massberg, S.; Enders, G.; de Melo Matos, F.C.; Tomic, L.I.D.; Leiderer, R.; Eisenmenger, S.; Messmer, K. & Krombach, F. 1999. Fibrinogen Deposition at The Postischemic Vessel Wall Promotes Platelet Adhesion During Ischemia-Reperfusion in Vivo. *Blood*, Vol.94, No.11, (December 1999), pp.3829–3838, ISSN:0006-4971.

Massberg, S.; Gawaz, M.; Grüner, S.; Schulte, V.; Konrad, I.; Zohlnhöfer, D.; Heinzmann, U. & Nieswandt, B. 2003. A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In Vivo. *The Journal of Experimental Medicine*, Vol.197, No.1, (January 2003), pp.41-49, ISSN:0022-1007.

May, A.E.; Kalsch, T.; Massberg, S.; Herouy, Y.; Schmidt, R. & Gawaz, M. 2002. Engagement of Glycoprotein IIb/IIIa (aIIb3) on Platelets Upregulates CD40L and Triggers CD40L-Dependent Matrix Degradation by Endothelial Cells. *Circulation*, Vol.106, No.16, (October 2002), pp.2111-2117, ISSN:0009-7322.

Methia, N.; Andre, P.; Denis, C.V.; Economopoulos, M. & Wagner, D.D. 2001. Localized Reduction of Atherosclerosis in Von Willebrand Factor-Deficient Mice. *Blood*, Vol.98, No.5, (September 2001), pp.1424–1428, ISSN:0006-4971.
Moons, A.H.M.; Levib, M. & Peters, R.J.G. 2002. Tissue Factor and Coronary Artery Disease. *Cardiovascular Research*, Vol. 53, No.2, (February 2002), pp.313-325, ISSN:0008-6363.

Nassar, T.; Sachais, B.S.; Akkawit, A.; Kowalska, M.A.; Bdeir, K.; Leitersdorf, E.; His, E.; Ziporen, L.; Aviram, M.; Cines, D.; Poncz, M. & Higazi, A.A. 2003. Platelet Factor 4 Enhances the Binding of Oxidized Low-density Lipoprotein to Vascular Wall Cells *The Journal of Biological Chemistry*, Vol.278, No.8, (February 2003), pp.6187-619, ISSN:0021-9258.

Neumann, F. J.; Zohlinhofer, D.; Fakhoury, L.; Ott, I.; Gawaz, M. & Schomig, A. 1999. Effect of Glycoprotein IIb/IIIa Receptor Blockade on Platelet-Leukocyte Interaction and Surface Expression of The Leukocyte Integrin Mac-1 in Acute Myocardial Infarction. *Journal of American College of Cardiology*, Vol.34, No.5, (November 1999), pp.1420–1426, ISSN:0735-1097.

Pitsilos, S.; Hunt, J.; Mohler, E.R.; Prabhakar, A.M.; Poncz, M.; Dawicki, J.; Khalapyan, T.Z.; Wolfe, M.L.; Fairman, R.; Mitchell, M.; Carpenter, J.; Golden, M.A.; Cines, D.B. & Sachais, B.S. 2003. Platelet Factor 4 Localization in Carotid Atherosclerotic Plaques: Correlation With Clinical Parameters. *Thrombosis and Haemostasis*, Vol.902, No.6, (December 2003), pp.1112-1120, ISSN:0340-6245.

Romo, G.M.; Dong, J.F.; Schade, A.J.; Gardiner, E.E., Kansas, G.S., Li, C.Q., McEntire, L.V., Berndt, M.C. & López, J.A. 1999. The Glycoprotein Ib-IX-V Complex is a Platelet Counterreceptor for P-selectin. *The Journal of Experimental Medicine*, Vol.190, No.6, (September 1999), pp.803-814, ISSN:0022-1007.

Ruggeri, Z.M. 2002. Platelets in Atherothrombosis. *Nature Medicine*, Vol.8, No.11, (November 2002), pp.1227-1234, ISSN:1078-8956.

Santoso, S.; Sachs, U.J.H.; Kroll, H.; Linder, M.; Ruf, A.; Preissner, K.T. & Chavakis, T. 2002. The Junctional Adhesion Molecule 3 (JAM-3) on Human Platelets is A Counterreceptor for The Leukocyte Integrin Mac-1. *The Journal of Experimental Medicine*, Vol.196, No.5, (September 2002), pp.679-691, ISSN:0022-1007.

Sarma, J.; Laan, C.A.; Alam, S.; Jha, A.; Fox, K.A.A. & Dransfield, I. 2002. Increased Platelet Binding to Circulating Monocytes in Acute Coronary Syndromes. *Circulation*, Vol.106, No.18, (May 2002), pp.2166-2171, ISSN:0009-7322.

Schober, A.; Manka, D.; von Hundelshausen, P.; Huo, Y.; Hanrath, P.; Sarembock, I.J.; Ley, K. & Weber, C. 2002. Deposition of Platelet RANTES Triggering Monocyte Recruitment Requires P-Selectin and is Involved in Neointima Formation After Arterial Injury. *Circulation*, Vol.106, No.12, (September 2002), pp.1523-1529, ISSN: 0009-7322.

Setianto, B.Y.; Hartopo, A.B.; Gharini, P.P.; Anggrahini, D.W. & Irawan, B. 2010. Circulating soluble CD40 ligand mediates the interaction between neutrophils and platelets in acute coronary syndrome. *Heart Vessels*, Vol.25, No.4, (July 2010), pp.282-287, ISSN: 0910-8327.
Sevitt, S. 1986. Platelets and Foam Cells in the Evolution of Atherosclerosis Histological and Immunohistological Studies of Human Lesions. *Atherosclerosis*, Vol.61, No.2, (August 1986), pp.107-115, ISSN:0021-9150.

Simionescu, M. & Simionescu, N. 1993. Proatherosclerotic Events: Pathobiochemical Changes Occurring in The Arterial Wall Before Monocyte Migration. *The FASEB Journal*, Vol.7, No.14, (November 1993), pp.1359-1366, ISSN:0892-6638.

Simon, D.I.; Chen, Z.; Xu, H.; Li, C.Q.; Dong, J.; McIntire, L.V.; Ballantyne, C.M.; Zhang, L.; Furman, M.I.; Berndt, M.C. & López, J.A. 2000. Platelet Glycoprotein Ib Alpha Is A Counterreceptor for The Leukocyte Integrin Mac-1 (CD11b/CD18). *The Journal of Experimental Medicine*, Vol.192, No.2, (July 2000), pp.193-204, ISSN:0022-1007.

Skålén, K.; Gustafsson, M.; Rydberg, E.K.; Hultén, L.M.; Wiklund, O.; Innerarity, T.L. & Borén, J. 2002. Subendothelial Retention of Atherogenic Lipoproteins in Early Atherosclerosis. *Nature*, Vol.417, No.13, (June 2002), pp.750-754, ISSN:0028-0836.

Slupsky, J.R.; Kalbas, M.; Willuweit, A.; Henm, V.; Krocze, R.A. & Müller-Berghaus, G. 1998. Activated Platelets Induce Tissue Factor Expression on Human Umbilical Vein Endothelial Cells By Ligation of CD40. *Thrombosis and Haemostasis*, Vol.80, No.6, (December 1998), pp.1008–1014, ISSN:0340-6245.

Sniderman, A.; Yu, H. & Cianflone, K. 1991. Effect of Moderate Hypertriglyceridemia on The Relation of Plasma Total and LDL Apo B Levels. *Atherosclerosis*, Vol.89, No.2-3, (August 1991), pp.109-116, ISSN: 0021-9150.

Stocker, R. & Keaney, J.F.Jr. 2004. Role of Oxidative Modifications in Atherosclerosis. *Physiological Review*, Vol.84, No.4, (October 2004), pp.1381-1478, ISSN: 0031-9333

Tabas, I.; Williams, K.J., & Borén, J. 2007. Subendothelial Lipoprotein Retention As the Initiating Process in Atherosclerosis: Update and Therapeutic Implications. *Circulation*, Vol.116, No.16, (October 2007), pp.1832-1844, ISSN:0009-7322.

Theilmeier, G.; Lenaerts, T.; REMACLE, C.; Collen, D.; Verrymelen, J. & Hoylaerts, M.F. 1999. Circulating Activated Platelets Assist THP-1 Monocytoid/Endothelial Cell Interaction Under Shear Stress. *Blood*, Vol.94, No.8, (October 1999), pp.2725-2724, ISSN:0006-4971.

Theilmeier, G.; Michiels, C.; Spaepen, E.; Vreys, I.; Collen, D.; Verrymelen, J. & Hoylaerts, M.F. 2002. Endothelial von Willebrand Factor Recruits Platelets To Atherosclerosis-Prone Sites in Response To Hypercholesterolemia. *Blood*, Vol.99, No.12, (June 2002), pp.4486-4493, ISSN:0006-4971.

Torzewski, M. & Lackner, K.J. 2006. Initiation and Progression of Atherosclerosis—Enzymatic or Oxidative Modification of Low-Density Lipoprotein? *Clinical Chemistry and Laboratory Medicine*, Vol.44, No.12, (December 2006), pp.1389–1394, ISSN: 1434-6621.

Ulrichs, H.; Vanoordelkebe, K.; Girma, J.P.; Lenting, P.J.; Vauterin, S. & Deckmyn, H. 2005. The Von Willebrand Factor Self-Association is Modulated By a Multiple Domain Interaction. *Journal of Thrombosis and Haemostasis*, Vol.3, No.3, (March 2005), pp.552-556, ISSN:1538-7933.

Vandendries, E.R.; Furie, B.C. & Furie, B. 2004. Role of P-selectin and PSGL-1 in Coagulation and Thrombosis. *Thrombosis and Haemostasis*, Vol.92, No.3, (September 2004), pp.459-466, ISSN:0340-6245.

Van Gils, J. M.; Zwaginga, J. J. & Hordijk, P. L. 2009. Molecular and Functional Interactions Among Monocytes, Platelets, and Endothelial Cells and Their Relevance for
Cardiovascular Diseases. *Journal of Leukocyte Biology*, Vol.85, No.3, (February 2009), pp.195–204, ISSN:0741-5400.

Virmani, R.; Kolodgie, F.D.; Burke, A.P.; Farb, A. & Schwartz, S.M. 2000. Lessons From Sudden Coronary Death: A Comprehensive Morphological Classification Scheme for Atherosclerotic Lesions. *Arteriosclerosis, Thrombosis, and Vascular Biology*, Vol.20, No.5, (May, 2000), pp.1262–1275, ISSN: 1079-5642.

Von Hundelshausen P, Weber KS, Huo Y, Proudfoot, A.E.I.; Nelson, P.J.; Ley, K. & Weber, C. 2001. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. *Circulation*, Vol.103, No.13, (April 2001), pp.1772–1777, ISSN:0009-7322.

Von Hundelshausen, P. & Weber, C. 2007. Platelets as Immune Cells Bridging Inflammation and Cardiovascular Disease. *Circulation Research*, Vol.100, No.1, (January 2007), pp. 27-40, ISSN:0009-7330.

Walz, A.; Schmutz, P.; Mueller, C. & Schnyder-Candrian, S. 1997. Regulation and Function of The CXC Chemokine ENA-78 Inmonocytes and Its Role in Disease. *Journal of Leukocyte Biology*, Vol.62, No.5 (November 1997), pp.604-611, ISSN:0741-5400.

Weyrich, A.S.; Prescott, S.M. & Zimmerman, G.A. 2002. Platelets, Endothelial Cells, Inflammatory Chemokines, and Restenosis Complex Signaling in the Vascular Play Book. *Circulation*, Vol. 106, No. 12, (September 2002), pp.1433-1435, ISSN:0009-7322.

Yu, G.; Rux, AH.; Ma, P.; Bdeir, K. & Sachais, B.S. 2005. Endothelial Expression of E-Selectin is Induced By The Platelet-Specific Chemokine Platelet Factor 4 Through LRP in An NF-Kappa b-Dependent Manner. *Blood*, Vol.105, No.9, (May 2005), pp. 3545–3551, ISSN:0006-4971.

Zillmann, A.; Luther, T.; Müller, I.; Kotzsch, M.; Spannagl, M.; Kauke, T.; Oelschlägel, U.; Zahler, S. & Engelmann, B. 2001. Platelet-Associated Tissue Factor Contributes to the Collagen-Triggered Activation of Blood Coagulation. *Biochemical and Biophysical Research Communications*, Vol. 281, No. 2, (February 2001), pp.603–609, ISSN: 0006-291X.
This book has been written with the intention of providing an up-to-the-minute review of acute coronary syndromes. Atherosclerotic coronary disease is still a leading cause of death within developed countries and not surprisingly, is significantly rising in others. Over the past decade the treatment of these syndromes has changed dramatically. The introduction of novel therapies has impacted the outcomes and surviving rates in such a way that the medical community need to be up to date almost on a “daily bases”. It is hoped that this book will provide a timely update on acute coronary syndromes and prove to be an invaluable resource for practitioners seeking new and innovative ways to deliver the best possible care to their patients.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Anggoro B. Hartopo, Budi Y. Setianto, Hariadi Hariawan, Lucia K. Dinarti, Nahar Taufiq, Erika Maharani, Irsad A. Arso, Hasanah Mumpuni, Putrika P.R. Gharini, Dyah W. Anggrahini and Bambang Irawan (2012). Plaque, Platelets, and Plug – The Pathogenesis of Acute Coronary Syndrome, Acute Coronary Syndromes, Dr. Mariano Brizzio (Ed.), ISBN: 978-953-307-827-4, InTech, Available from: http://www.intechopen.com/books/acute-coronary-syndromes/plaque-platelets-and-plug-the-pathogenesis-of-acute-coronary-syndrome
